ODACon™ Supportive Care Summit: Managing Toxicities of Novel Breast Cancer Therapies - HER2 Tyrosine Kinase Inhibitors

ODACon™ Supportive Care Summit: Managing Toxicities of Novel Breast Cancer Therapies - HER2 Tyrosine Kinase Inhibitors is organized by i3 Health and will be held from Dec 07, 2022 - Dec 06, 2023.,Statement of Need:,Breast cancer is the most common cancer diagnosed in women, and it is estimated that 15% of cases are HER2-positive and may therefore benefit from human epidermal growth factor receptor 2 (HER2) inhibition (ACS, 2019). By blocking downstream oncogenic signaling in HER2-positive breast cancer cells, HER2 tyrosine kinase inhibitors improve outcomes for patients with HER2-positive breast cancer. These agents have advantages over monoclonal antibody HER2 inhibitors because they are orally available and may have increased penetration of the brain to treat brain metastases. Additionally, the spectrums of kinase inhibition for each individual tyrosine kinase inhibitor produce unique efficacy and safety profiles, which may make them a good option for some patients (Schlam & Swain, 2021). Tyrosine kinase inhibitors are often used in combination with chemotherapy and other HER2-targeting agents, which complicates their management. This session will review data on HER2 tyrosine kinase inhibitors, including tucatinib and neratinib, and will compare their activity and safety profiles in combination with other medications for breast cancer. The faculty will highlight the differing considerations for management of patients taking these drugs.,Learning Objectives:,Upon completion of this activity, participants should be able to,In this session, Abbey Kaler, MS, APRN, FNP-C, Advanced Practice Registered Nurse in the Advanced Breast Cancer Program at the University of Texas MD Anderson Cancer Center, will review data on HER2 tyrosine kinase inhibitors, including tucatinib and neratinib, and will compare their activity and safety profiles in combination with other medications for breast cancer. She will also highlight the differing considerations for management of patients taking these drugs.